Episode 143: Why Animal Health Is the Next Frontier for Biotech Innovation
What can the world of animal health teach us about the future of biotech innovation, vaccine development, and global healthcare?
In this episode, Elaine Hamm, PhD, sits down with Patrik Erlmann, PhD, Global Head of Biological Development in Animal Health at Boehringer Ingelheim, to explore the role of drug development in animal health. Drawing from his experience in startups, human pharmaceuticals, and now animal health, Patrik shares how biologics are transforming veterinary medicine, why developing therapies for animals requires a different mindset, and where opportunities exist for researchers, startups, and academic innovators.
In this episode, you’ll discover:
- How animal health development differs from human pharmaceuticals and where the two industries overlap.
- Why vaccines and biologics are becoming increasingly important for improving animal health while combating antimicrobial resistance.
- What startups, universities, and technology transfer offices should know when developing innovations for the animal health market.
Tune in to discover why animal health is becoming one of biotech’s most exciting areas of innovation, and how breakthroughs in veterinary medicine can create benefits that extend far beyond the farm and the clinic.
Links:
Connect with Patrik Erlmann, PhD, and learn about Boehringer Ingelheim Animal Health.
Connect with Elaine Hamm, PhD, and learn about Tulane Medicine Business Development and the School of Medicine.
Connect with Ian McLachlan, BIO from the BAYOU producer.
Learn more about BIO from the BAYOU – the podcast.
Bio from the Bayou is a podcast that explores biotech innovation, business development, and healthcare outcomes in New Orleans & The Gulf South, connecting biotech companies, investors, and key opinion leaders to advance medicine, technology, and startup opportunities in the region.
